Relyvrio/Albrioza, Amylyx’s ill-fated treatment for amyotrophic lateral sclerosis, was approved for marketing by the US Food and Drug Administration but rejected by the European Medicines Agency. The Pink Sheet explores how the two agencies applied the available regulatory flexibilities and the impact of other factors, such as regulatory precedence and patient influence, on decision-making.
EU and US regulators took different approaches to regulatory flexibility when it came to Amylyx's ALS treatment • Source: Shutterstock
Is the risk of delaying patient access to a desperately needed potential treatment greater than the risk of facilitating access to an ineffective but relatively safe product? How important is regulatory precedence? And how much should patients influence the final outcome?
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.
The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.
Sponsors and regulatory agencies within the 27 EU member states must all be “committed” to working with the EU Clinical Trials Regulation in the most appropriate way to keep pace with other countries, including the UK where competition is heating up, says Miguel Forte, CEO of Kiji Therapeutics.
Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.
